MedTrace Logo

Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients

NCT04790968 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-11-15

No results posted yet for this study

Summary

For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment.

Standard treatment for these patients is radiotherapy or surgery. The surgery involves resection of the prostate and the pelvic lymph nodes. Currently, the most reliable method to confirm lymph node metastases is by histologic examination of the resected lymph nodes. Ideally, one should be able to detect lymph node metastases prior to treatment. Then, the treatment could be better adjusted to each patient.

Imaging methods such as prostate specific membrane antigen positron emission tomography (PSMA-PET) can possibly aid the detection of lymph node metastases. In this study, the investigators want to test whether PSMA-PET or a combination of PSMA-PET and MRI (magnetic resonance imaging) can improve staging of lymph nodes before treatment.

Conditions

  • Prostatic Neoplasms
  • Neoplasm Metastasis

Interventions

DIAGNOSTIC_TEST

PSMA-PET

Prostate specific membrane antigen positron emission tomography

DIAGNOSTIC_TEST

PSMA-PET/MRI

Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging

DIAGNOSTIC_TEST

PSMA-PET/CT

Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging

Sponsors & Collaborators

  • St. Olavs Hospital

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Øystein Risa, Prof · Norwegian University of Science and Technology, NTNU

  • Morten Troøyen, MD · St. Olavs Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04790968 on ClinicalTrials.gov